SCHEMBL5547171

SCHEMBL5547171

CCN(CC)C1CCN(c2ccc(O)cc2)CC1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.45
▸ MAPT P10636 3/20 0.45
▸ LMNA P02545 2/20 0.45
▸ GAA P10253 2/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ PKM P14618 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.44
▸ ME3 Q16798 2/20 0.43
▸ GFER P55789 1/20 0.41
▸ DRD4 P21917 1/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ HTT P42858 1/20 0.40
▸ CBX7 O95931 1/20 0.39
▸ CDYL2 Q8N8U2 1/20 0.39
▸ CDYL Q9Y232 1/20 0.39
▸ OPRD1 P41143 1/20 0.39
▸ USP2 O75604 1/20 0.38
▸ DRD2 P14416 3/20 0.37
▸ DRD3 P35462 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542766 0.87 DRD3 (0.48) MAPTLMNADRD4DRD2DRD3
SCHEMBL8728925 0.85 ADRB1 (0.46) MAPTLMNAGAAALDH1A1TDP1
SCHEMBL520505 0.83 MAPT (0.53) KDM4EMAPTLMNAGAAALDH1A1
SCHEMBL5547166 0.83 SMN1; SMN2 (0.39) MAPTSMN1; SMN2CBX7CDYL2CDYL
SCHEMBL8728922 0.83 L3MBTL3 (0.37) KDM4EMAPTGAAGFERSMN1; SMN2
SCHEMBL27995386 0.83 CHRNA7 (0.50) LMNASMN1; SMN2DRD2
SCHEMBL7303320 0.81 MAPT (0.51) KDM4EMAPTALDH1A1SMN1; SMN2USP2
SCHEMBL4696324 0.81 ACKR3 (0.35) DRD4SMN1; SMN2CBX7CDYL2CDYL
SCHEMBL5539933 0.81 KDM4E (0.49) KDM4EMAPTLMNAGAAALDH1A1
SCHEMBL27474246 0.79 ME3 (0.46) KDM4EMAPTLMNAGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 — — EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 — — EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 — — US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 — — US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 — — CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KDM4E 4854/4885MAPT 4117/4885LMNA 4152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback